Results 241 to 250 of about 169,027 (313)

Transcriptomic profiling of dorsal root ganglia in atopic and healthy dogs: A comparative RNA sequencing study with implications in cutaneous itch research

Veterinary Dermatology, EarlyView.
Background – Itch is a common symptom in skin disorders. While the neural pathways of itch transmission from the skin to the brain are well‐understood in rodents, the same pathways in dogs remain unclear. The knowledge gap hinders the development of effective treatments for canine itch‐related disorders.
Chie Tamamoto‐Mochizuki, Santosh K. Mishra   +1 more
wiley   +1 more source

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study. [PDF]

Nat Commun
Koester A, Witcher DR, Lee M, Demarest SJ, Potter S, Werle K, Bauer S, Ruiz D, Malherbe L, Poorbaugh J, Glasebrook A, Preuss C, Datta G, Wang Z, Knorr J, Manner D, Patel D, Schmitz C, Klekotka P, Nirula A.   +19 more
europepmc   +1 more source

Rational Design of Single‐Domain Antibodies Targeting the Central Nervous System Neurite Outgrowth Inhibitor Nogo‐A

Applied Research, Volume 4, Issue 3, June 2025.
The development of a nanobody for Nogo‐A, a potent neurite outgrowth inhibitor crucial in multiple sclerosis, is reported using a rational design approach. The nanobody targets the Nogo‐A ectodomain at the S1PR2 receptor‐binding region with submicromolar KD.
Vaidehi Roy Chowdhury, Alexander Röntgen, Matthew Greenig, Yanira Méndez Gómez, Sebastian P. Spiegel, Magdalena Nowinska, Aubin Ramon, Pietro Sormanni, Andrew Chan, Michele Vendruscolo   +9 more
wiley   +1 more source

Intestinal perforation in recurrent cervical cancer following bevacizumab and pembrolizumab therapy: A case report. [PDF]

Medicine (Baltimore)
Fan Y, Liu S, Zhao J, Fu Y, Yang J, Wang C, Zhang H.   +6 more
europepmc   +1 more source

Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial

International Journal of Cancer, Volume 156, Issue 11, Page 2178-2187, 1 June 2025.
What's new? Bone metastases are common in a variety of cancer types, causing increased pain and worse outcomes. Suppression of bone turnover, such as with the monoclonal antibody denosumab, results in fewer skeletal complications and improved prognosis. Here, the authors demonstrate the safety and efficacy of a similar antibody, JMT103. Like denosumab,
Ran Ran, Hongtao Li, Tao Sun, Huan Zhou, Aimin Zang, Hongqian Guo, Hua Xie, Shikai Wu, Yong Yan, Xing Yin, Hailin Xiong, Hong Li, Jing Yuan, Juan Wang, Huiping Li, Jin Li   +15 more
wiley   +1 more source

Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells. [PDF]

Oncol Res
Qiao C, Xu Y, He Y, Cai Z, Wang H.
europepmc   +1 more source

Characteristic, Regulation and Targeting Strategies of Cancer Stem Cells and Their Niche in Digestive System Tumors

MedComm – Oncology, Volume 4, Issue 2, June 2025.
Cancer stem cells, characterized by self‐renewal, differentiation, heterogeneity, plasticity and tumorigenicity, are regulated by intrinsic factors such as signaling pathways, transcription factors, metabolism and noncoding RNAs, as well as environmental cells (including tumor cells, immune cells and stromal cells), environmental factors and distant ...
Zhenzhen Chen, Huanle Qi, Yapeng Xue, Yaqi Zhang, Zhuo Zhang, Shun Xu, Shixin Liao, Xiaoyu Zeng, Jiayi Wu, Xinrui Lv, Qiankun He, Pingping Zhu   +11 more
wiley   +1 more source

Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies

European Journal of Haematology, Volume 114, Issue 6, Page 938-952, June 2025.
ABSTRACT The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity ...
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice. [PDF]

Virol J
Zhou C, Liao X, Zhou Z, Mo C, Yang Y, Liao H, Liu M, Zhang Q, Li Q, Tian X, Zhou R, Cao H.   +11 more
europepmc   +1 more source

Predictive and Prognostic Significance of Patient‐Reported Outcomes for Survival and Adverse Events in Daratumumab‐Treated Multiple Myeloma

European Journal of Haematology, Volume 114, Issue 6, Page 1020-1031, June 2025.
ABSTRACT Objectives Patient‐reported outcomes (PROs), including physical function, have predictive potential for survival but remain underexplored in multiple myeloma (MM). This study evaluates the predictive and prognostic value of PROs for treatment outcomes in MM patients on daratumumab‐based therapy and evaluates physical function versus ECOG ...
Ahmad Y. Abuhelwa, Sara A. Almansour, Ethan Basch, Humaid O. Al‐Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad H. Semreen, Zelal Kharaba, Salma M. Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross A. McKinnon, Michael J. Sorich, Karem H. Alzoubi, Ashley M. Hopkins   +14 more
wiley   +1 more source